Tetrahydrobiopterin (BH 4 ) is an endogenously synthesized cofactor, required for various enzyme activities and for some less well-defined functions. It is also required at the cellular level. The known enzymes that depend on BH 4 are phenylalanine hydroxylase (PAH), tyrosine hydroxylase, tryptophan hydroxylases 1 and 2, all three types of nitric oxide (NO) synthases (NOS), and glyceryl-ether monooxygenase (GEMO). At the cellular level, BH 4 was found to be a growth or proliferation factor for Crithidia fasciculata and a control factor for infectivity of Leishmania major. In the nervous system, BH 4 is a self-protecting factor for NO or a general neuroprotecting factor via the NOS pathway, and has dopamine-releasing function. The major controlling point of BH 4 biosynthesis is GTP cyclohydrolase I (GTPCH) whose expression may be under control of cytokine induction, and at least in liver, GTPCH activity is inhibited by BH 4 (and stimulated by phenylalanine) through the GTPCH feedback regulatory protein (GFRP). With regard to human disease, BH 4 deficiency (Fatypical PKU_) due to autosomal recessive mutations in all cofactormetabolizing enzymes (except sepiapterin reductase) is described as a cause of hyperphenylalaninaemia (HPA). Under normal conditions the intracellular BH 4 level is thought to play a pivotal role in not only the regulation of tyrosine and tryptophan hydroxylases, but also in the initial and rate-limiting steps in the biosynthesis of the catecholamines and serotonin.
Thus, alterations in BH 4 levels result in a disturbance of biogenic amine metabolism which has been implicated as an aetiological factor in a variety of neurological disorders. Mutations in the gene for GTPCH are closely related to Dopa-responsive dystonia (Segawa disease). This evidence strongly supports the importance of BH 4 and dopaminergic transmission in dystonia. Alterations in BH 4 metabolism have been observed in several neuropsychiatric diseases, such as Parkinson disease, familial dystonia, and endogenous depression, as well as in endothelial dysfunction, vitiligo, and more recently in pain perception. A subtype of PAH deficiency has been associated with BH 4 -responsiveness and mild or moderate phenylketonuria (PKU) due to specific mutations in the PAH gene, offering potential pharmacological treatment with BH 4 (sapropterine; Kuvan R ). Biomedical research on BH 4 expanded from the initial investigations in Fatypical PKU_ patients to neurodegeneration, pain, vascular-endothelial, and epidermal dysfunction including diabetes, and other disciplines. Regarding treatment approaches, the field has been extended from BH 4 -cofactor and pharmachaperon treatment to enzyme replacement and experimental gene therapy.
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